SyntheticMR ( ) - 株価, ニュースと分析NGM:SYNT

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

SYNT 株式概要

SyntheticMR AB (publ) engages in the development and marketing of imaging solutions for magnetic resonance imaging (MRI) in Sweden, the Middle East, Africa, Europe, North America, South America, and the Asia-Pacific.

会社概要

SYNT ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	5/6
過去の実績	3/6
財務の健全性	6/6
配当金	0/6

報酬

当社が推定した公正価値より34.4%で取引されている

収益は年間47.4%増加すると予測されています

過去1年間で収益は70.3%増加しました

リスク分析

株式の流動性は非常に低い

高いレベルの非現金収入

SyntheticMR AB (publ) 競合他社

RaySearch Laboratories

OM:RAY B

kr4.6b

Physitrack

OM:PTRK

kr275.6m

Kontigo Care

OM:KONT

kr71.1m

Sectra

OM:SECT B

kr46.7b

価格と性能

の歴代最高値、変動、値下がりまとめSyntheticMR
過去の株価
現在の株価	kr27.70
52週高値	kr34.90
52週安値	kr17.30
ベータ	0.96
11ヶ月の変化	0%
3ヶ月変化	1.09%
1年変化	-13.44%
33年間の変化	-40.69%
5年間の変化	6.54%
IPOからの変化	1,008.00%

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

Dec 20

Recent updates

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Nov 29

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Aug 06

Why SyntheticMR AB (publ) (NGM:SYNT) Could Be Worth Watching

Feb 23

A Look At The Intrinsic Value Of SyntheticMR AB (publ) (NGM:SYNT)

Jan 27

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

Nov 10

Read This Before Selling SyntheticMR AB (publ) (NGM:SYNT) Shares

Mar 09

What Percentage Of SyntheticMR AB (publ) (NGM:SYNT) Shares Do Insiders Own?

Feb 11

SyntheticMR AB (publ) (NGM:SYNT) Insiders Increased Their Holdings

Dec 03

株主還元

	SYNT	SE Healthcare Services	SE 市場
7D	0%	-5.8%	-3.4%
1Y	-13.4%	35.8%	14.3%

業界別リターン: SYNT過去 1 年間で35.4 % の収益を上げたSwedish Healthcare Services業界を下回りました。

リターン対市場: SYNTは、過去 1 年間で14.4 % のリターンを上げたSwedish市場を下回りました。

価格変動

Is SYNT's price volatile compared to industry and market?
SYNT volatility
SYNT Average Weekly Movement	n/a
Healthcare Services Industry Average Movement	5.5%
Market Average Movement	5.9%
10% most volatile stocks in SE Market	12.7%
10% least volatile stocks in SE Market	3.5%

安定した株価: SYNT過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: 過去 1 年間のSYNTのボラティリティの変化を判断するにはデータが不十分です。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2007	37	Ulrik Harrysson	www.syntheticmr.com

SyntheticMR AB (publ) 基礎のまとめ

SyntheticMR の収益と売上を時価総額と比較するとどうか。
SYNT 基礎統計学
時価総額	kr1.15b
収益（TTM）	kr10.01m
売上高(TTM)	kr94.37m

115.3x

PER（株価収益率

12.2x

P/Sレシオ

SYNT は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
SYNT 損益計算書（TTM）
収益	kr94.37m
売上原価	kr30.33m
売上総利益	kr64.05m
その他の費用	kr54.03m
収益	kr10.01m

直近の収益報告

Dec 31, 2023

次回決算日

May 21, 2024

一株当たり利益（EPS）	0.24
グロス・マージン	67.86%
純利益率	10.61%
有利子負債／自己資本比率	0%

SYNT の長期的なパフォーマンスは？

過去の実績と比較を見る

SYNT 株式概要

報酬

リスク分析

SyntheticMR AB (publ) 競合他社

OM:RAY B

kr4.6b

OM:PTRK

kr275.6m

OM:KONT

kr71.1m

OM:SECT B

kr46.7b

価格と性能

最新ニュース

SyntheticMR AB (publ) Announces Board Changes

SyntheticMR AB (publ) to Report Q1, 2024 Results on May 21, 2024

SyntheticMR AB (publ), Annual General Meeting, May 21, 2024

SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D

SyntheticMR AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

Recent updates

SyntheticMR AB (publ) Announces Board Changes

SyntheticMR AB (publ) to Report Q1, 2024 Results on May 21, 2024

SyntheticMR AB (publ), Annual General Meeting, May 21, 2024

SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D

SyntheticMR AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking

SyntheticMR Has Submitted Their Next Generation Solution, SyMRI 3D for 510(K) Clearance

SyntheticMR Appoints Nomination Committee for the 2024 Annual General Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

SyntheticMR AB (publ) to Report Nine Months, 2023 Results on Nov 10, 2023

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Now 22% undervalued after recent price drop

SyntheticMR AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Now 20% undervalued after recent price drop

SyntheticMR Releases A New Update to SyMRI 11.3.11 & 12.1.11

SyntheticMR Introduces Quantitative Neuro Reports to Enhance Clinical Workflow

SyntheticMR Receives Regulatory Approval for Their Innovative SyMRI Software Solution in South Korea

Consensus EPS estimates fall by 28%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Some Investors May Be Worried About SyntheticMR's (NGM:SYNT) Returns On Capital

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

Full year 2022 earnings released: EPS: kr0.15 (vs kr0.20 in FY 2021)

Now 24% undervalued after recent price drop

SyntheticMR AB (publ), Annual General Meeting, May 23, 2023

Consensus EPS estimates fall by 17%

Now 21% undervalued after recent price drop

SyntheticMR AB (publ) to Report Fiscal Year 2022 Results on Feb 15, 2023

Now 20% undervalued after recent price drop

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

No independent directors

Now 21% undervalued after recent price drop

SyntheticMR Receives EU Medical Device Regulation (Mdr) Certificate

SyntheticMR AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

SyntheticMR's SyMRI MSK Software for Knee and Spine Imaging Receives Regulatory Approval in Brazil

Consensus EPS estimates increase by 18%

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

Consensus EPS estimates fall by 14%

Consensus EPS estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

SyntheticMR AB (publ) to Report First Half, 2022 Results on Aug 23, 2022

SyntheticMR's Quantitative MRI Solution Symri Neuro Compatible with Philips Smartspeed to Support Shorter Scan Times

Dr. Jeff Miller Joins SyntheticMR's Medical Advisory Board

SyMRI MSK from SyntheticMR is Now Available on syngo.via Open Apps from Siemens Healthineers

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 19%

Price target decreased to kr36.00

No independent directors

Full year 2021 earnings: EPS misses analyst expectations

SyntheticMR AB (publ), Annual General Meeting, May 10, 2022

SyntheticMR AB (publ) to Report Q1, 2022 Results on May 10, 2022

Now 24% undervalued after recent price drop

Syntheticmr AB (Publ) Announces Net Sales Guidance for the First Quarter 2022